• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Neovacs

edit

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France’s most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs’ therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

Recent Milestones

edit

• 
  Neovacs received $17.9M (€13M) in Venture Round funding. (7/17/07)
  Posted 3/12/10 at 8:31pm via neovacs.fr

Videos

Screenshots

edit

Above: Neovacs
Uploaded: 3/13/10

Sources

1. Neovacs, a leading biotech company in the field of therapeutic vaccines in oncology and inflammatory diseases, raises 13 million Euros from a international group of specialist investors, including the Novartis Venture Fund and Truffle Capital (neovacs.fr) [edit]